AbbVie to acquire Roche spinout Nimble for $200M upfront
by
Contributor since / Followers
Contributor since / Followers
1 week ago
hapabapa
- AbbVie (NYSE:ABBV) has agreed to acquire Roche (OTCQX:RHHBY) spinout Nimble Therapeutics for $200M upfront, plus a potential milestone payment.
- AbbVie (NYSE:ABBV) said the deal includes Nimble’s lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis.
- It also calls for AbbVie (ABBV) to provide interim funding to Nimble. The amount of the potential milestone payment was not disclosed.
- Nimble’s founding investors include Telegraph Hill Partners and Roche Ventures. The company was spun out of Roche (OTCQX:RHHBY) in 2019.